

# Opioid Overdose:

## Risk Factors

**Naloxone is indicated for the emergency treatment of known or suspected opioid overdose. Start the conversation by letting patients know about naloxone and discuss the risks associated with opioid overdose. Offer naloxone when the following factors that increase risk for opioid overdose are present:**\*1,2

- use of prescription opioids, especially doses  $\geq 50$  morphine milligram equivalents MME/daily
- use of opioids in combination with other sedating substances, such as benzodiazepines
- a suspected or confirmed history of substance abuse, dependence or non-medical use of prescription or illicit opioids

For these patients, **recommend that an emergency treatment for opioid overdose be in their home or with a caregiver/loved one.**

\*Adapted from World Health Organization: Substance Abuse Information Sheet on Opioid Overdose, 2014, and Centers for Disease Control and Prevention: CDC Guideline for Prescribing Opioids for Chronic Pain, 2014.

This resource is brought to you by Adapt Pharma, Inc.

For more information, contact our customer service department at **1 (844) 462-7226**.

## **NARCAN® NASAL SPRAY INDICATIONS AND IMPORTANT SAFETY INFORMATION**

### **INDICATIONS**

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.

### **IMPORTANT SAFETY INFORMATION**

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

**Please see additional Important Safety Information on reverse.**

## NARCAN® NASAL SPRAY INDICATIONS AND IMPORTANT SAFETY INFORMATION

### INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.

### IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized

by body aches, fever, sweating, runny nose, sneezing, goose bumps (piloerection), yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure and increased heart rate (tachycardia). In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

See Instructions for Use and full Prescribing Information in the use of this product, available here: <http://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf>.

Additional information, including full Prescribing Information for NARCAN® Nasal Spray, and Important Safety Information and Instructions for Use, is also available at [www.NARCAN.com](http://www.NARCAN.com).

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**References:** 1. World Health Organization. Substance Abuse Information Sheet on Opioid Overdose: [http://www.who.int/substance\\_abuse/information-sheet/en/](http://www.who.int/substance_abuse/information-sheet/en/). Accessed February 2017. 2. CDC Guideline for Prescribing Opioids for Chronic Pain. [https://www.cdc.gov/drugoverdose/pdf/guidelines\\_at-a-glance-a.pdf](https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-a.pdf). Accessed February 2017.